<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692042</url>
  </required_header>
  <id_info>
    <org_study_id>D0980C00001</org_study_id>
    <nct_id>NCT00692042</nct_id>
  </id_info>
  <brief_title>Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704</brief_title>
  <official_title>A Phase I, First Time in Man, Single-Centre, Randomised, Double-Blind (Within Panels), Placebo-Controller Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1704 After Administration of Oral Single Ascending Doses in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim for this study is to investigate the safety and tolerability of the AZD1704,
      first time in man.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the safety and tolerability of AZD1704 following single ascending doses in healthy volunteers.</measure>
    <time_frame>At screening, during residential period (daily) and at follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the subjective CNS effects of specific adjectives (stimulated, anxious, sedated, down and high) rated on visual analogue mood scale (VAMS).</measure>
    <time_frame>During residential period (daily)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1704</intervention_name>
    <description>One dose, by mouth</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers, man or woman of non child-bearing potential

          -  Provision of signed informed consent.

        Exclusion Criteria:

          -  History of somatic disease/condition that may interfere with the objectives ot the
             study, as judged by the Investigator. History of seizures, with the exception of
             single occasions fever induced seizures in childhood.

          -  History of previous or ongoing psychiatric disease/condition including psychosis,
             affective disorder, anxiety disorder, borderline state and personality disorder
             according to the criteria in the DSM of Mental Disorder, 4th edition

          -  History of use of antipsychotic, antidepressant or anxiolytic drugs for the treatment
             of psychiatric disease or symptoms, prescribed as well as non-prescribed use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Billy Fahy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca R&amp;D CPU Nottingham, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Ståhle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D Södertälje, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reserach Site</name>
      <address>
        <city>Macclesfield</city>
        <state>Cheshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>June 23, 2008</last_update_submitted>
  <last_update_submitted_qc>June 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Rolf Karlsten, MD, PhD, Medical Science Director, Emerging Analgesia, Neuroscience</name_title>
    <organization>AstraZeneca R&amp;D Södertälje, Sweden</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

